Grünenthal
↗Aachen, Germany
Grünenthal is a global leader in pain management and a science-based, fully integrated pharmaceutical company. Headquartered in Aachen, Germany, the company specializes in the research, development, and commercialization of innovative non-opioid pain treatments and established brands. It covers the entire pharmaceutical value chain, from target identification and clinical development to manufacturing and global distribution.
Founded in 1946, Grünenthal remains a family-owned enterprise that has transformed its business model since 2017 through significant M&A activity and a focused R&D strategy. The company is particularly known for its expertise in neuropathic pain, osteoarthritis, and chronic post-surgical pain, and it operates a major Innovation Hub in Boston to tap into the global biotech ecosystem.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:€1.8B
Founded:1946
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Total Raised:$852.9M
Investors:Wirtz Family (Owners), NovaQuest Capital Management (R&D Partner)
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 3
Modalities:Small molecule, Topical system, Intra-articular injection, Glucocorticoid Receptor Modulator (GRM)
Active Trials:157
Trial Phases:Phase 1: 12 | Phase 2: 8 | Phase 3: 5 | Phase 4: 10
FDA Approvals:5
EMA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:Averitas Pharma (USA), Grünenthal Meds (Joint Venture), Laboratorios Andrómaco (Chile), Tecnandina S.A. (Ecuador)
Key Partnerships:Kyowa Kirin (Joint Venture for established brands), NovaQuest Capital Management (R&D funding for RTX), SHL Medical (Autoinjector assembly), Apotex (Canadian distribution for Qutenza and Nebido), Eli Lilly (LatAm rights for Cialis)
COMPETITION
Position:Leader
Competitors:Pfizer, Endo International, UCB, Salix Pharmaceuticals, Cara Therapeutics, Hisamitsu Pharmaceutical
LEADERSHIP
Key Executives:
Gabriel Baertschi - CEO
Fabian Raschke - CFO
Uli Brödl, MD - CSO
Scientific Founders:Hermann Wirtz, Sr. (Founder)
Board Members:Pär Johansson (Chairman of the Board), Martin Zügel (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Grünenthal. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.